Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Pediatr Hematol Oncol. 2012 Jul 27;29(6):568–578. doi: 10.3109/08880018.2012.708708

Table I. Patient, donor, and graft characteristics.

Pt Age
at
HCT
(yrs)
Ethnicity Time
from
dx to
HCT (yrs)
Abn
Cyto-
genetics
RBC/Platelet
transfusions
Androgen
therapy
Donor
status
to
patient
HLA Matching ABO
Pt/
Donor
CMV
status
Pt /
Donor
CD34
cell
dose/kg
(106)
TNC
dose/kg
(108)
Class I Class II
Patient
Donor
A B C DRB1 DQ
1 13 Brazilian-Mixed 2.5 No 50/>70(ferritin 13,000) Yes Half-sib 02CMZW/31CNSK 44AJVH/5201 05ANJN/0102 040701/160201 0301/0301 B+/B+ +/+ 2.21 5.27
02CMZW/31CNSK 35AEYZ/5201 03CRCV/0102 1402/160201 0301/0301

2 6 Hispanic 2.5 No 0/1 No Mother 11AGWS/11AGWS 27AHUV/35HNH 01FJJ/12NP 0404/0408 03BG/0304 O−/O− +/+ 3.69 4.46
11AGWS/02AGSM 35HNH/35ASNB 12NP/04CZYV 0408/1602 0304/03CFTD

3 11 Brazilian-Mixed 1.5 No 5/3 (ferritin 1000) Yes (significant virilization) Cousin 1101/3001 3501g/5501 0303/20N /0401g 0103/0301 0501/0201 AB+/O+ +/+ 4.41 5.38
0301/3001 3501g/5501 0303/20N /0401g 0103/0301 0501/0201